Emphysema Treatment Market Expected to Reach $8.7 Billion by 2032

According to a new report published by Allied Market Research, titled, “Emphysema Treatment Market," The emphysema treatment market was valued at $6.3 billion in 2022, and is estimated to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Increase in prevalence of COPD is expected to drive the growth of the global emphysema market. For instance, according to the report of Global Initiative for Chronic Obstructive Lung Disease 2022, estimated 200 million people suffer from COPD, with majority of cases occurring in low-income countries. Rise in prevalence of exposure to secondhand smoke and chemicals contributes to rise in emphysema cases, which results in demand for early diagnosis and treatment, thus leading to market growth. For instance, according to an article published in the National Library of Medicine 2021, lifelong secondhand smoke exposure caused 2.9% rise in risk of development of chronic obstructive pulmonary disease disorder. 

In addition, exposure to biomass fuel and air pollution contributes to the rising prevalence of COPD, which results in need for appropriate treatment with medications, which is anticipated to notably contribute toward the growth of the global market.For instance, according to an article published in the National Library of Medicine 2022, 3 billion people are exposed to smoke from incomplete combustion of biomass fuel across the world, resulting in risk of development of COPD. Rise in awareness about COPD and its symptoms is important as early diagnosis and treatment can improve quality of life, thereby driving the emphysema treatment market forecast.

For instance, according to National Heart, Lung, and Blood Institute, 2020, educational awareness programs are organized to promote better understanding of COPD and are also the upcoming emphysema treatment market trends. In addition, Reckitt (specialty pharma in U.S.) launched a new education and early detection campaign for patients with undiagnosed COPD in 2022, which results in rise in COPD cases. Rise in awareness about symptoms and early diagnosis of COPD is expected to drive the demand for efficient treatment option for COPD. 

Furthermore, new products with less side effects for emphysema treatment are launched, which is anticipated to contribute to the growth of the emphysema treatment market. For instance, in November 2023, Global pharma major, Lupin announced the launch of Vilfuro-G, the world’s first fixed-dose triple combination drug (FDC) for the treatment of COPD in India. Vilfuro-G is available in a single-strength fixed dose, with a recommended once-daily dosage for the treatment of COPD, which refers to a group of diseases that cause airflow blockage and breathing-related problems. 
 
The global emphysema treatment market analysis is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy and surgery. The medication is further bifurcated into type and distribution channel. On the basis of type, it is fragmented into centriacinar, panacinar, and others. Depending on end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of treatment type, the medication segment dominated emphysema treatment market share in 2022 and is expected to remain dominant during the forecast period owing high adoption and easy availability of medications for treating emphysema. Medication includes pharmaceutical interventions aimed at managing the symptoms and progression of emphysema. These medications include bronchodilators to help open airways, corticosteroids to reduce inflammation, and antibiotics to manage infections. In addition, medications offer a relatively non-invasive and accessible treatment option for patients, especially to those in the early stages of the disease or those seeking to manage their symptoms without undergoing surgery.

Depending on type, the centriacinar segment dominated emphysema treatment market share in 2022 and is expected to continue this trend during the forecast period. This is attributed to the fact that centriacinar is one of the most prevalent forms of emphysema, particularly among smokers, who represent a significant portion of the population affected by this condition. Centriacinar is characterized by damage primarily to the central or proximal portions of the acinus within the lungs. In addition, the chronic and progressive nature of centriacinar emphysema necessitates ongoing management and treatment, thereby driving the demand for therapeutic interventions and pharmaceuticals targeted at improving respiratory function and quality of life for affected individuals.

By end user, the homecare segment dominated the emphysema treatment market size in 2022 and is expected to dominate the market during the forecast period. This is attributed to availability of medications which can be used in home settings and advancements in medical technology that have enabled the development of portable and user-friendly devices for managing emphysema symptoms at home. In addition, the devices such as portable oxygen concentrators and handheld inhalers empower patients to take greater control of their treatment regimen without the need for frequent visits to healthcare facilities. This shift toward home-based care aligns with the growing preference for patient-centric healthcare models, where individuals seek more convenient and comfortable options for managing their chronic conditions.

Region wise, North America dominated the emphysema treatment market size in 2022 owing to the strong presence of key players, well-developed healthcare infrastructure, and rise in prevalence of emphysema. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period due to increasing prevalence, initiatives for early diagnosis and increasing healthcare investments.

Key findings of the study

• By treatment type, the medication segment was the major shareholder in the emphysema treatment industry in 2022.

• On the basis of type, the centriacinar segment is expected to exhibit the fastest market growth during the forecast period.

• Depending on end user, the homecare segment acquired the largest share in emphysema treatment industryin 2022.

• Region wise, North America held the largest market share in 2022; however, Asia-Pacific is expected to witness the highest CAGR during the forecast period.